The Year in Lipid Disorders.:
Lipid disorders are among the primary risk factors in developing atherosclerosis and heart disease. Providing an up-to-date insight into the latest research into lipid disorders, and the implications of this research for daily clinical practice, this collection includes an overview of the latest dev...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Oxford :
Clinical Pub.,
2010.
|
| Schriftenreihe: | Year in Lipid Disorders.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Lipid disorders are among the primary risk factors in developing atherosclerosis and heart disease. Providing an up-to-date insight into the latest research into lipid disorders, and the implications of this research for daily clinical practice, this collection includes an overview of the latest developments in this complex field by reviewing the most significant papers published in the medical journals on lipid disorders over the last eighteen months. |
| Beschreibung: | 1 online resource (333 pages). |
| Bibliographie: | Includes bibliographical references and indexes. |
| ISBN: | 9781846926228 184692622X 9781846920615 1846920612 1282727427 9781282727427 9786612727429 661272742X |
Internformat
MARC
| LEADER | 00000cam a2200000Mu 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn693761617 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr |n|---||||| | ||
| 008 | 101220s2010 enk ob 001 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d N$T |d OCLCQ |d OCLCF |d UKDOC |d OCLCQ |d YDXCP |d OCLCQ |d AGLDB |d OCLCQ |d VTS |d TOF |d STF |d M8D |d OCLCQ |d VLY |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 698132381 |a 1086902166 |a 1162282050 |a 1241887523 |a 1264963452 |a 1297131645 |a 1297625130 |a 1300515303 |a 1303347521 |a 1303521858 | ||
| 020 | |a 9781846926228 | ||
| 020 | |a 184692622X | ||
| 020 | |a 9781846920615 |q (electronic bk.) | ||
| 020 | |a 1846920612 |q (electronic bk.) | ||
| 020 | |a 1282727427 | ||
| 020 | |a 9781282727427 | ||
| 020 | |a 9786612727429 | ||
| 020 | |a 661272742X | ||
| 035 | |a (OCoLC)693761617 |z (OCoLC)698132381 |z (OCoLC)1086902166 |z (OCoLC)1162282050 |z (OCoLC)1241887523 |z (OCoLC)1264963452 |z (OCoLC)1297131645 |z (OCoLC)1297625130 |z (OCoLC)1300515303 |z (OCoLC)1303347521 |z (OCoLC)1303521858 | ||
| 050 | 4 | |a RC632.L5 |b Y43 2010eb | |
| 072 | 7 | |a MED |x 027000 |2 bisacsh | |
| 072 | 7 | |a MED |x 060000 |2 bisacsh | |
| 082 | 7 | |a 616.3997 |2 22 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Toth, Peter P. | |
| 245 | 1 | 4 | |a The Year in Lipid Disorders. |
| 260 | |a Oxford : |b Clinical Pub., |c 2010. | ||
| 300 | |a 1 online resource (333 pages). | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Year in Lipid Disorders | |
| 505 | 0 | |a Contents; Editors; Contributors; Part 1: Clinical aspects ofatherosclerotic disease; Chapter 1: Proprotein convertase subtilisin/kexin type 9 (PCSK9): molecular function and impact of its mutations and polymorphisms on cholesterol levels and related diseases; Chapter 2: Metabolic syndrome, diabetes and cardiovascular risk; Chapter 3: Diet and exercise in the prevention and treatment of diabetes and coronary heart disease; Chapter 4: Imaging developments in vascular disease; Part II: Lipids, lipoproteins and atherosclerosis. | |
| 505 | 8 | |a Chapter 5: Ezetimibe: mechanism of action update and recent controversiesChapter 6: Oxidative stress, lipoprotein oxidation and atherosclerosis; Chapter 7: Updating the metabolism of apolipoprotein B-100- containing lipoproteins in dyslipidaemia; Chapter 8: Triglycerides and atherosclerosis; Part III: Prevention and treatment strategies; Chapter 9: JUPITER: the crossroads between statin therapy, inflammation and cardiovascular risk reduction; Chapter 10: New clinical trials of lipid regulatingagents; Chapter 11: Statin myopathy. | |
| 505 | 8 | |a Chapter 12: Nuclear receptors (PPARs, LXRs and TRs) and their role in regulating lipid metabolismPart IV: Infection, inflammation and secondary causes of atherosclerosis; Chapter 13: Inflammation, inflammatory disease and coronary atherosclerosis; Chapter 14: Mechanisms of insulin resistance; Chapter 15: Haemostasis-dyslipidaemia interactions in coronary heart disease; Acronyms/abbreviations; Index of papers reviewed; General index. | |
| 520 | |a Lipid disorders are among the primary risk factors in developing atherosclerosis and heart disease. Providing an up-to-date insight into the latest research into lipid disorders, and the implications of this research for daily clinical practice, this collection includes an overview of the latest developments in this complex field by reviewing the most significant papers published in the medical journals on lipid disorders over the last eighteen months. | ||
| 504 | |a Includes bibliographical references and indexes. | ||
| 588 | 0 | |a Print version record. | |
| 546 | |a English. | ||
| 650 | 0 | |a Lipidoses. |0 http://id.loc.gov/authorities/subjects/sh85077295 | |
| 650 | 0 | |a Lipids |x Research. |0 http://id.loc.gov/authorities/subjects/sh85077299 | |
| 650 | 2 | |a Lipidoses |0 https://id.nlm.nih.gov/mesh/D008064 | |
| 650 | 6 | |a Dyslipoïdose. | |
| 650 | 7 | |a MEDICAL |x Endocrinology & Metabolism. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Nutrition. |2 bisacsh | |
| 650 | 7 | |a Lipidoses |2 fast | |
| 650 | 7 | |a Lipids |x Research |2 fast | |
| 758 | |i has work: |a The Year in Lipid Disorders (Text) |1 https://id.oclc.org/worldcat/entity/E39PCXC7tJr8ytRbD6RcyQTFdj |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Toth, Peter P. |t Year in Lipid Disorders. |d Oxford : Clinical Publishing, ©2010 |z 9781846920615 |
| 830 | 0 | |a Year in Lipid Disorders. | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=343868 |3 Volltext |
| 938 | |a 123Library |b 123L |n 15630 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL617575 | ||
| 938 | |a EBSCOhost |b EBSC |n 343868 | ||
| 938 | |a YBP Library Services |b YANK |n 3555597 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn693761617 |
|---|---|
| _version_ | 1816881747404521472 |
| adam_text | |
| any_adam_object | |
| author | Toth, Peter P. |
| author_facet | Toth, Peter P. |
| author_role | |
| author_sort | Toth, Peter P. |
| author_variant | p p t pp ppt |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC632 |
| callnumber-raw | RC632.L5 Y43 2010eb |
| callnumber-search | RC632.L5 Y43 2010eb |
| callnumber-sort | RC 3632 L5 Y43 42010EB |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Contents; Editors; Contributors; Part 1: Clinical aspects ofatherosclerotic disease; Chapter 1: Proprotein convertase subtilisin/kexin type 9 (PCSK9): molecular function and impact of its mutations and polymorphisms on cholesterol levels and related diseases; Chapter 2: Metabolic syndrome, diabetes and cardiovascular risk; Chapter 3: Diet and exercise in the prevention and treatment of diabetes and coronary heart disease; Chapter 4: Imaging developments in vascular disease; Part II: Lipids, lipoproteins and atherosclerosis. Chapter 5: Ezetimibe: mechanism of action update and recent controversiesChapter 6: Oxidative stress, lipoprotein oxidation and atherosclerosis; Chapter 7: Updating the metabolism of apolipoprotein B-100- containing lipoproteins in dyslipidaemia; Chapter 8: Triglycerides and atherosclerosis; Part III: Prevention and treatment strategies; Chapter 9: JUPITER: the crossroads between statin therapy, inflammation and cardiovascular risk reduction; Chapter 10: New clinical trials of lipid regulatingagents; Chapter 11: Statin myopathy. Chapter 12: Nuclear receptors (PPARs, LXRs and TRs) and their role in regulating lipid metabolismPart IV: Infection, inflammation and secondary causes of atherosclerosis; Chapter 13: Inflammation, inflammatory disease and coronary atherosclerosis; Chapter 14: Mechanisms of insulin resistance; Chapter 15: Haemostasis-dyslipidaemia interactions in coronary heart disease; Acronyms/abbreviations; Index of papers reviewed; General index. |
| ctrlnum | (OCoLC)693761617 |
| dewey-full | 616.3997 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.3997 |
| dewey-search | 616.3997 |
| dewey-sort | 3616.3997 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04723cam a2200673Mu 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn693761617</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |n|---|||||</controlfield><controlfield tag="008">101220s2010 enk ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">EBLCP</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCF</subfield><subfield code="d">UKDOC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">YDXCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">AGLDB</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VTS</subfield><subfield code="d">TOF</subfield><subfield code="d">STF</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VLY</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">698132381</subfield><subfield code="a">1086902166</subfield><subfield code="a">1162282050</subfield><subfield code="a">1241887523</subfield><subfield code="a">1264963452</subfield><subfield code="a">1297131645</subfield><subfield code="a">1297625130</subfield><subfield code="a">1300515303</subfield><subfield code="a">1303347521</subfield><subfield code="a">1303521858</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781846926228</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">184692622X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781846920615</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1846920612</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1282727427</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781282727427</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9786612727429</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">661272742X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)693761617</subfield><subfield code="z">(OCoLC)698132381</subfield><subfield code="z">(OCoLC)1086902166</subfield><subfield code="z">(OCoLC)1162282050</subfield><subfield code="z">(OCoLC)1241887523</subfield><subfield code="z">(OCoLC)1264963452</subfield><subfield code="z">(OCoLC)1297131645</subfield><subfield code="z">(OCoLC)1297625130</subfield><subfield code="z">(OCoLC)1300515303</subfield><subfield code="z">(OCoLC)1303347521</subfield><subfield code="z">(OCoLC)1303521858</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC632.L5</subfield><subfield code="b">Y43 2010eb</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">027000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">060000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.3997</subfield><subfield code="2">22</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Toth, Peter P.</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Year in Lipid Disorders.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Oxford :</subfield><subfield code="b">Clinical Pub.,</subfield><subfield code="c">2010.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (333 pages).</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Year in Lipid Disorders</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Contents; Editors; Contributors; Part 1: Clinical aspects ofatherosclerotic disease; Chapter 1: Proprotein convertase subtilisin/kexin type 9 (PCSK9): molecular function and impact of its mutations and polymorphisms on cholesterol levels and related diseases; Chapter 2: Metabolic syndrome, diabetes and cardiovascular risk; Chapter 3: Diet and exercise in the prevention and treatment of diabetes and coronary heart disease; Chapter 4: Imaging developments in vascular disease; Part II: Lipids, lipoproteins and atherosclerosis.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 5: Ezetimibe: mechanism of action update and recent controversiesChapter 6: Oxidative stress, lipoprotein oxidation and atherosclerosis; Chapter 7: Updating the metabolism of apolipoprotein B-100- containing lipoproteins in dyslipidaemia; Chapter 8: Triglycerides and atherosclerosis; Part III: Prevention and treatment strategies; Chapter 9: JUPITER: the crossroads between statin therapy, inflammation and cardiovascular risk reduction; Chapter 10: New clinical trials of lipid regulatingagents; Chapter 11: Statin myopathy.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 12: Nuclear receptors (PPARs, LXRs and TRs) and their role in regulating lipid metabolismPart IV: Infection, inflammation and secondary causes of atherosclerosis; Chapter 13: Inflammation, inflammatory disease and coronary atherosclerosis; Chapter 14: Mechanisms of insulin resistance; Chapter 15: Haemostasis-dyslipidaemia interactions in coronary heart disease; Acronyms/abbreviations; Index of papers reviewed; General index.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Lipid disorders are among the primary risk factors in developing atherosclerosis and heart disease. Providing an up-to-date insight into the latest research into lipid disorders, and the implications of this research for daily clinical practice, this collection includes an overview of the latest developments in this complex field by reviewing the most significant papers published in the medical journals on lipid disorders over the last eighteen months.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and indexes.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Lipidoses.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85077295</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Lipids</subfield><subfield code="x">Research.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85077299</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Lipidoses</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D008064</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Dyslipoïdose.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Endocrinology & Metabolism.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Nutrition.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lipidoses</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lipids</subfield><subfield code="x">Research</subfield><subfield code="2">fast</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">The Year in Lipid Disorders (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCXC7tJr8ytRbD6RcyQTFdj</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Toth, Peter P.</subfield><subfield code="t">Year in Lipid Disorders.</subfield><subfield code="d">Oxford : Clinical Publishing, ©2010</subfield><subfield code="z">9781846920615</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Year in Lipid Disorders.</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=343868</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">123Library</subfield><subfield code="b">123L</subfield><subfield code="n">15630</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL617575</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">343868</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">3555597</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn693761617 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:17:38Z |
| institution | BVB |
| isbn | 9781846926228 184692622X 9781846920615 1846920612 1282727427 9781282727427 9786612727429 661272742X |
| language | English |
| oclc_num | 693761617 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (333 pages). |
| psigel | ZDB-4-EBA |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Clinical Pub., |
| record_format | marc |
| series | Year in Lipid Disorders. |
| series2 | Year in Lipid Disorders |
| spelling | Toth, Peter P. The Year in Lipid Disorders. Oxford : Clinical Pub., 2010. 1 online resource (333 pages). text txt rdacontent computer c rdamedia online resource cr rdacarrier Year in Lipid Disorders Contents; Editors; Contributors; Part 1: Clinical aspects ofatherosclerotic disease; Chapter 1: Proprotein convertase subtilisin/kexin type 9 (PCSK9): molecular function and impact of its mutations and polymorphisms on cholesterol levels and related diseases; Chapter 2: Metabolic syndrome, diabetes and cardiovascular risk; Chapter 3: Diet and exercise in the prevention and treatment of diabetes and coronary heart disease; Chapter 4: Imaging developments in vascular disease; Part II: Lipids, lipoproteins and atherosclerosis. Chapter 5: Ezetimibe: mechanism of action update and recent controversiesChapter 6: Oxidative stress, lipoprotein oxidation and atherosclerosis; Chapter 7: Updating the metabolism of apolipoprotein B-100- containing lipoproteins in dyslipidaemia; Chapter 8: Triglycerides and atherosclerosis; Part III: Prevention and treatment strategies; Chapter 9: JUPITER: the crossroads between statin therapy, inflammation and cardiovascular risk reduction; Chapter 10: New clinical trials of lipid regulatingagents; Chapter 11: Statin myopathy. Chapter 12: Nuclear receptors (PPARs, LXRs and TRs) and their role in regulating lipid metabolismPart IV: Infection, inflammation and secondary causes of atherosclerosis; Chapter 13: Inflammation, inflammatory disease and coronary atherosclerosis; Chapter 14: Mechanisms of insulin resistance; Chapter 15: Haemostasis-dyslipidaemia interactions in coronary heart disease; Acronyms/abbreviations; Index of papers reviewed; General index. Lipid disorders are among the primary risk factors in developing atherosclerosis and heart disease. Providing an up-to-date insight into the latest research into lipid disorders, and the implications of this research for daily clinical practice, this collection includes an overview of the latest developments in this complex field by reviewing the most significant papers published in the medical journals on lipid disorders over the last eighteen months. Includes bibliographical references and indexes. Print version record. English. Lipidoses. http://id.loc.gov/authorities/subjects/sh85077295 Lipids Research. http://id.loc.gov/authorities/subjects/sh85077299 Lipidoses https://id.nlm.nih.gov/mesh/D008064 Dyslipoïdose. MEDICAL Endocrinology & Metabolism. bisacsh MEDICAL Nutrition. bisacsh Lipidoses fast Lipids Research fast has work: The Year in Lipid Disorders (Text) https://id.oclc.org/worldcat/entity/E39PCXC7tJr8ytRbD6RcyQTFdj https://id.oclc.org/worldcat/ontology/hasWork Print version: Toth, Peter P. Year in Lipid Disorders. Oxford : Clinical Publishing, ©2010 9781846920615 Year in Lipid Disorders. FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=343868 Volltext |
| spellingShingle | Toth, Peter P. The Year in Lipid Disorders. Year in Lipid Disorders. Contents; Editors; Contributors; Part 1: Clinical aspects ofatherosclerotic disease; Chapter 1: Proprotein convertase subtilisin/kexin type 9 (PCSK9): molecular function and impact of its mutations and polymorphisms on cholesterol levels and related diseases; Chapter 2: Metabolic syndrome, diabetes and cardiovascular risk; Chapter 3: Diet and exercise in the prevention and treatment of diabetes and coronary heart disease; Chapter 4: Imaging developments in vascular disease; Part II: Lipids, lipoproteins and atherosclerosis. Chapter 5: Ezetimibe: mechanism of action update and recent controversiesChapter 6: Oxidative stress, lipoprotein oxidation and atherosclerosis; Chapter 7: Updating the metabolism of apolipoprotein B-100- containing lipoproteins in dyslipidaemia; Chapter 8: Triglycerides and atherosclerosis; Part III: Prevention and treatment strategies; Chapter 9: JUPITER: the crossroads between statin therapy, inflammation and cardiovascular risk reduction; Chapter 10: New clinical trials of lipid regulatingagents; Chapter 11: Statin myopathy. Chapter 12: Nuclear receptors (PPARs, LXRs and TRs) and their role in regulating lipid metabolismPart IV: Infection, inflammation and secondary causes of atherosclerosis; Chapter 13: Inflammation, inflammatory disease and coronary atherosclerosis; Chapter 14: Mechanisms of insulin resistance; Chapter 15: Haemostasis-dyslipidaemia interactions in coronary heart disease; Acronyms/abbreviations; Index of papers reviewed; General index. Lipidoses. http://id.loc.gov/authorities/subjects/sh85077295 Lipids Research. http://id.loc.gov/authorities/subjects/sh85077299 Lipidoses https://id.nlm.nih.gov/mesh/D008064 Dyslipoïdose. MEDICAL Endocrinology & Metabolism. bisacsh MEDICAL Nutrition. bisacsh Lipidoses fast Lipids Research fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85077295 http://id.loc.gov/authorities/subjects/sh85077299 https://id.nlm.nih.gov/mesh/D008064 |
| title | The Year in Lipid Disorders. |
| title_auth | The Year in Lipid Disorders. |
| title_exact_search | The Year in Lipid Disorders. |
| title_full | The Year in Lipid Disorders. |
| title_fullStr | The Year in Lipid Disorders. |
| title_full_unstemmed | The Year in Lipid Disorders. |
| title_short | The Year in Lipid Disorders. |
| title_sort | year in lipid disorders |
| topic | Lipidoses. http://id.loc.gov/authorities/subjects/sh85077295 Lipids Research. http://id.loc.gov/authorities/subjects/sh85077299 Lipidoses https://id.nlm.nih.gov/mesh/D008064 Dyslipoïdose. MEDICAL Endocrinology & Metabolism. bisacsh MEDICAL Nutrition. bisacsh Lipidoses fast Lipids Research fast |
| topic_facet | Lipidoses. Lipids Research. Lipidoses Dyslipoïdose. MEDICAL Endocrinology & Metabolism. MEDICAL Nutrition. Lipids Research |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=343868 |
| work_keys_str_mv | AT tothpeterp theyearinlipiddisorders AT tothpeterp yearinlipiddisorders |